CapyFin

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: This platform provides information and recommendations for educational purposes only and is not a substitute for professional financial advice. Our content covers a range of investment classes, including stocks and cryptocurrencies, and we do not guarantee the completeness, accuracy, reliability, or suitability of this information, which may include data from third-party services and content generated by artificial intelligence (AI). Investing in stocks, cryptocurrencies, and other financial instruments involves risks, including the potential loss of principal. Users should independently verify all information and seek advice from qualified professionals tailored to their individual financial situations and investment objectives. Our content and services are provided "as is" without any warranties, express or implied. We are not liable for any losses or damages arising from the use of our services. This disclaimer is subject to change; users are advised to review it periodically. Usage of our services constitutes acceptance of these terms.

Immunome Fiscal Q4 2023 Earnings Report - CapyFin

🇺🇸 NASDAQ:IMNM

Overview Earnings Dividends Seasonality Metrics

Apr 02, 2024

•

Dec 31, 2023

Immunome Q4 2023 Earnings Report

Immunome reported full-year 2023 financial results and provided an update on recently acquired assets.

Key Takeaways

Immunome reported its full-year 2023 financial results, highlighting a transformative year marked by the merger with Morphimmune, pipeline advancement, and leadership expansion. The company is focused on developing its existing assets and expanding the pipeline with novel ADCs and RLTs.

Closed the merger with Morphimmune.

Advanced the company's pipeline.

Expanded the company’s leadership team.

Acquired two promising assets and completed a successful financing.

Previous year: -$0.64

Research and development expenses

General and administrative expenses

In-process R&D expenses

Cash and Equivalents

Previous year: $20.3M

Previous year: -$6.76M

Previous year: $24M

Immunome

Unlock previous datapoints

Immunome

Unlock previous datapoints

Revenue by Segment

Collaboration Revenue

CapyFin.com

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Company Overview

Full financial data and analysis

Immunome Revenue by Segment